IP Library Granted Patent US 7,393,875
Granted Patent B2
US 7,393,875 · App. 10/429,198 · Granted Jul 1, 2008

Methods and compounds for inhibiting amyloid deposits

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,393,875
App. No.
10/429,198
Granted
Jul 1, 2008
Kind
B2
Abstract

Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

Claims (9)

1. A method for treating type II diabetes in a subject, comprising administering to said subject a therapeutically effective amount of 3-dimethylamino-1-propanesulfonic acid or a pharmaceutically acceptable salt thereof, such that said type II diabetes is treated.

2. The method of claim 1 , wherein 3-dimethylamino-1-propanesulfonic acid is administered to the subject.

3. The method of claim 1 , wherein the pharmaceutically acceptable salt is 3-dimethylamino-1-propanesulfonic acid sodium salt.

4. The method of claim 1 , wherein the administration is oral.

5. The method of claim 2 , wherein the administration is oral.

6. The method of claim 1 , wherein the subject is human.

7. The method of claim 1 , wherein pancreatic function is improved.

8. The method of claim 1 , wherein IAPP-associated amyloid deposition is reduced.

9. The method of claim 2 , wherein IAPP-associated amyloid deposition is reduced.

Assignments (5)
CHANGE OF NAME Recorded Jul 31, 2008
From: NEUROCHEM (INTERNATIONAL) LIMITED
To: BELLUS HEALTH (INTERNATIONAL) LIMITED
Reel/Frame 021373/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2007
From: SZAREK, WALTER A.; WEAVER, DONALD F.
To: QUEEN'S UNIVERSITY AT KINGSTON
Reel/Frame 018960/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2007
From: MIGNEAULT, DAVID; KONG, XIANQI; GUPTA, AJAY
To: NEUROCHEM, INC.
Reel/Frame 018960/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2006
From: QUEEN'S UNIVERSITY AT KINGSTON
To: NEUROCHEM (INTERNATIONAL) LIMITED
Reel/Frame 018668/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2003
From: NEUROCHEM, INC.
To: NEUROCHEM (INTERNATIONAL) LIMITED
Reel/Frame 014250/0732 →